Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | RET | P07949 | 3/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576481 | 0.90 | CNR2 (0.52) | CNR2METKCNH2AOC3 | |
| SCHEMBL15459629 | 0.88 | RET (0.42) | CNR2HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL15453292 | 0.79 | SLC6A7 (0.36) | CNR2JAK2RETALKCHEK1 | |
| SCHEMBL14621462 | 0.78 | PTGS2 (0.44) | — | |
| SCHEMBL3578845 | 0.76 | PTGS2 (0.38) | — | |
| SCHEMBL3577254 | 0.74 | PTGS2 (0.47) | — | |
| SCHEMBL3475014 | 0.74 | RXRA (0.56) | CNR2RETALKADRB2NMT1 | |
| SCHEMBL3573107 | 0.74 | KDM4E (0.40) | CNR2 | |
| SCHEMBL3587973 | 0.73 | PTGS2 (0.42) | — | |
| SCHEMBL15459627 | 0.72 | RET (0.49) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000022-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2015-04-07 | — | — | US | claimed |
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-02-06 | — | — | US | claimed |
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | claimed |
| US-9000022-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000022-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2015-04-07 | — | — | US | disclosed |
| US-9000022-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2015-04-07 | — | — | US | disclosed |
| EP-1910308-B1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-09-03 | — | — | EP | disclosed |
| EP-1910308-B1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2014-09-03 | — | — | EP | disclosed |
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569352-B2 | Imidazole based LXR modulators | EXELIXIS PATENT COMPANY LLC (US) | 2013-10-29 | — | — | US | disclosed |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| WO-2007002563-A1 | IMIDAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038964-A1 | IMIDAZOLE BASED LXR MODULATORS | NR1H2, NR1H3, NR1H4 | CNR2 135/4885HTR3E 1552/4885HTR3B 749/4885 |
| US-20100075964-A1 | IMIDAZOLE BASED LXR MODULATORS | NR1H2, NR1H3, NR1I2 | CNR2 138/4885HTR3E 1264/4885HTR3B 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.